Wednesday, August 30, 2023
hVIVO plc, a prominent player in the field of human challenge clinical trials for infectious and respiratory diseases, has revealed its strategic plan to establish a centralized facility in the thriving life sciences hub of Canary Wharf, London. This expansion, strongly backed by hVIVO clients, arises from the company's substantial increase in its order book and the growing demand for its human challenge trial services.
Cutting-Edge Complex with Growth Potential
The upcoming state-of-the-art facility will span two floors and serve as a comprehensive hub, featuring quarantine bedrooms, advanced laboratories, an outpatient unit, and corporate offices. With an initial capacity of 50 quarantine beds, the facility is positioned for potential expansion to accommodate up to 70 beds in the future. This specialized and secure establishment empowers hVIVO to concurrently conduct multiple challenge trials. Additionally, the on-site outpatient unit will facilitate Phase II and III field trials. The advanced virology and immunology laboratories will enhance sample throughput, broadening hVIVO's service offerings and extending its involvement with a wider range of pathogens.
Smooth Transition and Positive Financial Outlook
The initial phase of the new facility is anticipated to be completed in Q1 2024, with full operational status projected by Q2 2024. During this transition, hVIVO's existing Whitechapel and Queen Mary Bioenterprises Centre (QMB) clinics will continue operations, ensuring uninterrupted service for clients. Moreover, hVIVO's Plumbers Row and Manchester FluCamp screening facilities and outpatient unit will remain accessible as hubs for potential volunteers. The heightened demand, propelled by clients' eagerness to advance their studies and prepare for larger challenge trials, has translated into substantial customer funding for the facility. The revamped layout consolidates quarantine beds on a single floor within a unified building, optimizing revenue generation, staffing, operational costs, and overall efficiency.
Championing Research in Infectious and Respiratory Diseases
This strategic move to a larger, more advanced facility underscores hVIVO's unwavering commitment to advancing research in infectious and respiratory diseases. By harnessing state-of-the-art infrastructure and expanding capabilities, hVIVO aims to achieve significant breakthroughs in human challenge clinical trials. Furthermore, the new facility seamlessly aligns with the company's Environmental, Social, and Governance (ESG) objectives.
Yamin 'Mo' Khan, CEO of hVIVO, exudes excitement about the transition: "Our upcoming state-of-the-art facility represents a transformative milestone. With increased capacity, growth potential, and expanded capabilities, we are excellently positioned to enhance revenue streams and operational efficiency. This consolidation will amplify our ability to conduct concurrent trials, broaden our service range, and optimize profitability."
Source:polaris.brighterir.com
